Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Development
AstraZeneca licenses small-molecule heart drug from China’s CSPC
by Sarah Braner
October 20, 2024
| A version of this story appeared in
Volume 102, Issue 33
AstraZeneca has licensed a small-molecule lipoprotein disruptor from China’s CSPC Pharmaceutical Group for $100 million. The molecule is intended to prevent formation of lipoprotein(a), high concentrations of which are thought to contribute to heart disease. AstraZeneca says the molecule could be used for multiple cardiovascular diseases and may be combined with AZD0780, a PCSK9 inhibitor it is developing to treat high lipid levels. CSPC could reap up to $1.92 billion in milestone payments.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X